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Abstract
Pregnancy is a diabetogenic state manifested by insulin resistance and hyperglycae-
mia. The age group at risk of getting gestational diabetes is between 20 and 39 years in 
96.8% of cases. Gestational diabetes is the development of symptoms and signs of diabe-
tes mellitus during pregnancy and the glucose level reverting to normal during puerpe-
rium. Depending on the type of population and the diagnostic criteria used, gestational 
diabetes is said to complicate 1–16% of all pregnancies. Many researchers in American, 
European and Asian surveys have reported 3–6% of prevalence. Compared with white 
European women, the prevalence rate for GD is increased approximately elevenfold in 
women from the Indian subcontinent, eightfold in South East Asia, sixfold and threefold 
in Arab and black Afro-Caribbean women, respectively. Such figures draw a potent 
clinical interest towards gestational diabetes (GD), and this chapter attempts to highlight 
some major aspects of GD in respect to both the mother and the foetus or the newborn 
specially emphasizing on its management as per the World Health Organization (WHO) 
and International Federation of Gynaecology and Obstetrics (FIGO).
Keywords: antenatal care, hyperinsulinaemia, impaired glucose tolerance, 
International Federation of gynaecology and obstetrics, medical nutrition therapy
1. Introduction
Gestational diabetes (GD) is characterised with impaired glucose tolerance 
(IGT) whose first recognition or onset is during pregnancy. International statistics 
claim that out of 10 pregnancies, at least 1 is associated with diabetes, most of 
which are GD. Lack 0f diagnosis or treatment of GD can lead to significant mater-
nal and foetal complications. Moreover, women with GD and their offsprings are 
comparatively at higher risk of developing type 2 diabetes later [1–10].
The incidence of GD is expected to increase at an expedited rate in the near future, 
amounting to one in every five pregnant women suffering from GD. According to a 
field study conducted in one of the Indian states under the ‘Diabetes in Pregnancy’—
Awareness and Prevention project, in most of the pregnant women screened in 
urban, semiurban and rural areas, respectively, the prevalence of GD was reported to 
be 17.8% in the urban, 13.8% in the semiurban and 9.9% in the rural areas [11–16].
GD may result in development of many pregnancy-associated disorders like 
polyhydramnios, pre-eclampsia, prolonged labour, obstructed labour, caesarean 
section, uterine atony, postpartum haemorrhage, infection and progression of reti-
nopathy which are the leading global causes of maternal morbidity and mortality. 
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Moreover, GD could also pose foetal risks including spontaneous abortion, intra-
uterine death, stillbirth, congenital malformation, birth injuries, neonatal hypogly-
caemia and infant respiratory distress syndrome.
Long-term clinical effects of GD are important contributors to the burden of 
non-communicable diseases in many countries [17, 18].
2. Aetiology and pathophysiology of GD
During normal pregnancy, resistance to insulin action increases. In most pregnan-
cies, the pancreas is able to meet the increased insulin demands, and normal blood 
glucose level is maintained. On the contrary, women who develop GD have impaired 
beta-cell response resulting in insufficient insulin secretion to meet the increased 
insulin demands. The following factors tend to enhance the chances of developing GD:
• Age: Due to age-related decreased pancreatic beta-cell reserve.
• Obesity: Leads to increased insulin resistance, which is further compounded by 
pregnancy.
• Smoking: Increases insulin resistance and decreases insulin secretion.
• Polycystic ovarian syndrome: Associated with insulin resistance and obesity.
• Nonwhite ancestry.
• Family history of type 2 diabetes.
• Intake of diet with low-fibre and high-glycaemic index.
• Weight gain.
• Lack of physical activity: Exercise increases insulin sensitivity.
• Prior GD: GD recurs in as many as 80% of subsequent pregnancies.
Products of the placenta, including tumour necrosis factor-alpha (TNF-α) 
and human chorionic somatomammotropin, are considered to play pathological 
roles in inducing maternal insulin resistance. Insulin resistance is observed at peak 
levels in the third trimester of pregnancy. Women who develop GD have pathologi-
cally impaired beta-cell function that leaves them with inability of adapting to 
pregnancy. In GD, as in type 2 diabetes, the deficit in beta-cell function is usually 
multifactorial and polygenetic. However, unmasked by the increased insulin needs 
of pregnancy, autoimmune diabetes and maturity-onset diabetes of youth (MODY) 
may occasionally be first recognised as GD. Hyperglycaemia in late pregnancy is 
associated with macrosomia and neonatal hypoglycaemia, hyperbilirubinemia and 
hypocalcaemia, as well as adverse maternal outcomes, including gestational hyper-
tension, pre-eclampsia and caesarean delivery [19–35].
3. Strategical diagnosis of GD
Profound international evidences and standard protocols suggest definite guidelines 
for screening pregnant women for GD.
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The American and Canadian guidelines recommend universal screening by 
two-step approach. This includes a screening with 50-g 1-hour blood glucose test 
(>140 mg/dL taken as screen positive). Women who screen positive are subjected 
to 100-g oral glucose tolerance test (OGTT), and those with 2 or more abnormal 
values of blood glucose are diagnosed with gestational diabetes.
Similarly, the National Institute for Health and Care Excellence (NICE), UK, 
and Australian guidelines recommend a slightly different risk-based screening.  
It recommends a 75-g 2-hour OGTT. Women with fasting blood glucose ≥126 mg/dL  
and postprandial (PP) blood glucose ≥140 mg/dL are diagnosed with  
GD [36, 37].
The WHO and International Federation of Gynaecology and Obstetrics (FIGO) 
endorse universal screening for GD at 24–28 weeks of gestation using the 75-g 
2-hour blood sugar (fasting ≥126 mg/dL and PP ≥140 mg/dL).
Almost all guidelines agree to the management of GD using medical nutri-
tion therapy (MNT) which is a standard diet plan for GD-diagnosed mothers 
and insulin therapy if required. Recently, global evidences have also concluded 
that the traditional biguanide—metformin—is safe and effective for GD  
management after 20 weeks of gestation if blood glucose level is not controlled 
alone by MNT [38–42].
GD pregnant women should be managed by medical nutrition therapy (MNT) 
and metformin or insulin therapy as required. In the postpartum period, OGTT must 
be repeated at 6 weeks post delivery; if blood glucose is <140 mg/dL, then women 
should be referred for postprandial blood glucose (PPBS) testing annually [43, 44].
3.1 Testing and management of GD
Ideally, all pregnant women should be screened for gestational diabetes, espe-
cially those who have one or more risk factors discussed above.
Trained human resources are required to manage the cases after diagnosis. 
Testing for GD is recommended twice during ante natal care (ANC).
The first testing should be done during the first antenatal contact as early as 
possible in pregnancy. If the first test result is negative, the test must be repeated 
between the second and third trimester of pregnancy. It is important to conduct a 
second test as most pregnant women develop blood glucose intolerance during this 
period (24–28 weeks). Mostly, one third of all GD-positive women are diagnosed 
during the first trimester. Hence, the test is repeated after the second trimester.
There should be at least a gap of 4 weeks between the two tests. The test should 
be conducted for all pregnant women even if she comes late in pregnancy for 
ANC. However, if the woman is over 28 weeks of pregnancy, only one test should be 
conducted if it is her first visit for ANC [45–51].
3.2 Methodology for diagnosis
The following stepwise protocol complies with the WHO guidelines for screening 
of pregnant women:
• The test is conducted with intake of 75 g of oral glucose dissolved in approximately 
300 mL of water, irrespective of whether the pregnant woman comes in fasting 
or non-fasting state, followed by measuring the blood glucose level by a plasma-
standardised glucometer after 2 hours of ingestion (postprandial blood glucose).
• If within 30 minutes of oral glucose intake the mother vomits, the test has to be 
repeated the next day. If vomiting occurs after 30 minutes, the test continues.
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• The threshold blood glucose level of ≥140 mg/dL is considered as limit for  
diagnosis of GD [52–61].
4. Internationally acceptable guidelines for management of GD
4.1 Guiding principles
All pregnant women who screen positive for GD in the first test are subjected to 
medical nutrition therapy (MNT) and physical exercise for 2 weeks. The woman is 
advised to walk or exercise for at least 30 minutes a day.
After 2 weeks on MNT and physical exercise, a 2-hour PPBS (post meal) should 
be done. All standardised protocols for management of GD suggest initial manage-
ment with MNT and physical exercise strictly. If diabetes is not controlled with 
MNT (lifestyle changes) alone, metformin or insulin therapy is recommended.
If 2-hour PPBS is <120 mg/dL, the test is to be repeated as per high-risk preg-
nancy protocol, i.e. to undertake eight tests (four regular tests and four additional). 
It is recommended to conduct at least one test every month during the second and 
third trimester. More follow-up tests can be done as recommended by the gynaeco-
logist. If 2-hour PPBS is ≥120 mg/dL, medical management (metformin or insulin 
therapy) has to be started as per guidelines (Figure 1) [62–66].
Figure 1. 
Standard health management protocol for pregnant women with GD.
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4.2 Medical nutrition therapy (MNT)
4.2.1 Healthy eating during pregnancy
All pregnant women with GD should get medical nutrition therapy (MNT) 
as soon as diagnosis is made. MNT for GD primarily involves a carbohydrate-
controlled balanced meal plan which promotes:
• Optimal nutrition for maternal and foetal health
• Adequate energy for appropriate gestational weight gain
• Achievement and maintenance of normoglycaemia [67, 68]
4.3 The significance of the individualised nutrition plan assessment in GD
Assessment of diet or nutrition plan in GD is an important criterion for diagno-
sis and subsequent follow-up on mother’s and foetus’ development. The nutrition 
plan must be individualised from patient to patient so that accurate appraisal of the 
woman’s nutritional status could be assessed. This assessment includes defining her 
body mass index (BMI) or percentage of desirable weight during pre-pregnancy to 
the optimal weight gain during the entire tenure of pregnancy [24, 69].
4.4 Monitoring calorie intake in GD
The energy demand of the body during pregnancy increases many times than 
that in a nonpregnant state. Individualization of nutritional requirement proves to 
be very helpful in determining the energy requirement and making amendments in 
the diet plan based on weight change patterns.
Normally calorie monitoring is not a point of concern in the first trimester 
unless a woman is underweight. It becomes more significant during the second and 
third trimester to monitor the energy requirements. Calorie intake should suffice 
the appropriate weight gain during gestation.
Ideally, for an average woman, weight gain of 10–12 kg is considered normal 
during pregnancy; an additional 350 kcal/day intake to the adult requirement is 
recommended during the second and third trimester.
Severe caloric restriction is strictly prohibited as it may cause ketonaemia and 
ketonuria in the mother as well as impair physical and mental growth in the off-
spring (Tables 1 and 2)[70–72].
Energy requirement can be calculated as follows:
  Energy requirement  (kcal / day) = BMR × PAL  (1)
*BMR = basal metabolic rate; *PAL = physical activity level.
where the basal metabolic rate (BMR) for an adult female in the age group of 
18–30 years is calculated as 14 × BW (kg) + 471 and similarly BMR for adult females 
of age group 30–60 years as 8.3 × BW (kg) + 788 (*BW = body weight).
4.4.1 Daily intake of carbohydrates
Carbohydrates are essential for both the mother and the baby. They are the 
ultimate source of glucose in the blood. Hence, the nature, quantity and frequency 
of carbohydrate intake influence greatly the blood glucose level.
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The carbohydrates must be evenly distributed through the daily food chart foods 
in order to avoid high blood glucose level. It is better to spread carbohydrate foods 
over three small meals and two to three snacks each day than taking three large 
meals [8, 73–78].
Complex carbohydrates (like whole-grain cereals like oats, vegetables and fruits) 
should be preferred over simple carbohydrates like food with lots of added sugar or 
honey. Also keeping a record of the number of carbohydrate serves that a mother 
eats during the day helps her to eat the right amount of carbohydrates [79].
4.4.2 Daily intake of fats
Overall fat intake by a pregnant woman should be planned in a manner that 
saturated fat such as butter, coconut oil, palm oil, red meat, organ meat and full 
cream milk amounts to less than 10% of total calories. The dietary cholesterol must 
be less than 300 mg/dL. In obese and overweight patients, a lower-fat diet overall 
can help slow the rate of weight gain [80].
4.4.3 Daily intake of proteins
Proteins are a very important dietary element for the growth and health of the 
foetus.
At least three servings of protein foods are recommended every day to meet the 
increased demand. Milk and milk products, egg, fish, chicken, pulses, nuts, etc. are 
all rich sources of protein that a mother can take during her pregnancy [80].
5. Pharmacotherapy of GD with metformin and insulin
The widely accepted treatment protocol for gestational diabetes advocates 
metformin or insulin therapy for clinical management of pregnant women diag-
nosed with GD that is not well controlled with MNT alone. Insulin is the first drug 
of choice for GD mothers.
The advantage of insulin therapy over metformin is that it can be started any 
time during pregnancy for GD management. If the gestation is less than 20 weeks, 
S. no. Body mass index Calorie requirement
1. <18.5 (underweight) Calorie requirement as per activity + 500 kcal/day
2. 18.5–22.9 (normal) Calorie requirement as per activity
3. 23–24.9 (overweight) Calorie requirement as per activity
4. >25 (obese) Calorie requirement as per activity—500 kcal/day
Table 2. 
Calorie requirement according to body mass index (BMI).
S. no. Nature of lifestyle Energy requirement during pregnancy Total energy requirement (kcal/day)
1. Sedentary 1900 + 350 2250
2. Moderately active 2230 + 350 2580
3. Highly active 2850 + 350 3200
Table 1. 
Energy requirement in relation to nature of lifestyle.
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and medical nutrition therapy (MNT) is not effective in controlling blood glucose 
levels, insulin should be started, but metformin can be considered only after 
20 weeks of gestation for clinical management of GD.
Metformin therapy can be started at 20 weeks of pregnancy, if MNT has not 
been able to control blood glucose alone. In the cases where the woman’s blood 
glucose is not controlled even with the maximum dose of metformin and MNT, the 
therapy must be switched to insulin therapy. The dose of metformin is 500 mg BID 
orally up to a maximum dose up to 2 g/day.
The incidence of hypoglycaemia and weight gain with metformin is less than 
insulin. If insulin is required in high doses, metformin may be added to the treat-
ment. Any pregnant women on insulin therapy should be instructed to keep sugar/
glucose powder handy at home to treat hypoglycaemia if it occurs [81–84].
5.1 Common side effects with metformin
• Diarrhoea
• Nausea
• Stomach pain
• Heartburn
• Lactic acidosis
• Low blood glucose
5.2 Types of insulins
Unlike the nonpregnant patients with diabetes who have a plethora of choices to 
achieve glucose control, the pregnant cases with GD offer a big challenge to the cli-
nicians when it comes to the choice of drugs for its management. In the recent years, 
we have come across a variety in new insulins, novel delivery systems and additional 
concentrations of existing insulins. With an alarming increase in the gestational 
diabetic population, the demands of the newer insulins will be ever increasing; 
hence, understanding these insulins becomes crucial. Additional pharmacokinetic 
and pharmacodynamic studies of these insulins in pregnancy are also required [85].
5.2.1 Short-acting insulin and rapid-acting insulin analogues
5.2.1.1 Regular (U-100) insulin
It is identical to human insulin and is synthesised in Escherichia coli bacteria. It 
is used before meal to compensate for heavy carbohydrates. The onset of action is 
around 30 minutes but can range from 10 to 75 minutes. The peak action is achieved 
at 3 hours (range 20 minutes to 7 hours), and the overall duration of action is 
~8 hours. U-100 vials can stay at room temperature for 31 days [86].
5.2.1.2 Regular (U-500) insulin
It is identical to human insulin but more concentrated than the U-100 formulation; 
its pharmacokinetic profile differs from U-100 as well. The onset is ~30 minutes, but 
the duration of action can last up to 24 hours. Severe hypoglycaemia may occur 24 hours 
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after the initial dose, although there are clinical reports suggesting that in pregnancy, 
severe hypoglycaemia is rare with U-500 insulin. Two to three injections daily are 
required, and a U-500 vial is good for 40 days at room temperature while in use [87–89].
5.2.1.3 Insulin aspartate
It is produced in a type of yeast, Saccharomyces cerevisiae, and is homologous 
to human insulin. It should be taken 5–10 minutes prior to meals. It can be 
administered as injections or in an insulin pump. The time of peak concentration 
ranges between 40 and 50 minutes, and the duration of action is 3–5 hours. It is 
also available in the forms of pens, penfills and vials that retain their pharma-
cological potency for at least 28 days at room temperature while in use. The risk 
of developing hypoglycaemia with insulin aspartate is less than regular insulin, 
although patients allergic to yeast must avoid it as this could potentially cause a 
site reaction [90].
5.2.1.4 Insulin lispro (U-100 and U-200)
It is an analogue produced in Escherichia coli. Its onset of action is 10–15 minutes, 
peak action is attained in 30–90 minutes and the duration of action is 3–4 hours. 
Intraperitoneal injections are preferred for the maximum absorption and shortest 
duration of action. It can be used in the form of insulin pumps or as multiple daily 
injections. The U-100 and U-200 formulations are bioequivalent, having the same 
pharmacokinetics. Insulin lispro U-200 is only available in pens to avoid administra-
tion errors. Pens, penfills and vials can be stored for 28 days at room temperature 
while in use [91].
5.2.2 Intermediate insulin and long-acting insulin analogues
5.2.2.1 Insulin isophane (NPH)
It is a U-100, intermediate-acting insulin. It is produced in Escherichia coli 
and is identical to human insulin available as a suspension. The onset of action is 
1–2 hours, with an average peak action of 4 hours (range, 4–8 hours). Duration of 
action lasts for 10–20 hours. Vials remain usable for 31 days at room temperature, 
whereas pens can be used for 14 days [92].
5.2.2.2 Insulin detemir (U-100)
This is a long-acting analogue of insulin produced in S. cerevisiae. One of the set-
backs with this formulation is that it can potentially cause a reaction in patients who are 
allergic to yeast. Detemir lacks a defined peak of action, but the pharmacological action 
lasts for up to 20 hours. The time to onset of action ranges between 1 and 2 hours. The 
pen and vial can be used up to 42 days at room temperature while in use. The chances 
of developing hypoglycaemia with detemir are less than NPH in pregnant women [93].
5.2.2.3 Insulin glargine (U-100)
It is a long-acting analogue produced in Escherichia coli. It differs from other con-
temporaries in terms of its distribution in plasma; the acidic solution is neutralised in 
subcutaneous tissue to form microprecipitates. These microprecipitates slowly release 
glargine over a duration of 24 hours, resulting in no well-defined peak. Its onset of 
action is 1–2 hours. Vials and pens are reusable for 28 days at room temperature.
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5.2.2.4 Insulin degludec U-100 and U-200
They are long-acting analogues approved by the US Food and Drug 
Administration (FDA) in September 2015. The U-100 and the U-200 are consid-
ered bioequivalent. Insulin degludec is extracted by means of recombinant DNA 
technology implemented in S. cerevisiae, to avoid potential reaction to the yeast, 
if allergic. Insulin degludec’s slow absorption into blood and prolonged action are 
attributed to the formation of soluble multi-hexamers. Its onset of action is ~1 hour 
and takes 8 days to reach steady state, and, once achieved, its duration of action 
lasts for 42 hours. It is usually administered once daily at any time of the day due to 
its long duration of action. Noncompliant patients may inject their dose at intervals 
of 8–40 hours without significant decreases in glycosylated haemoglobin (HbA1C) 
compared to taking it at the same time every day. U-100 degludec and U-200 
degludec are only dispensed in pens to decrease administration errors. Pens are 
good for up to 56 days at room temperature while in use [93].
5.3 Novel drug delivery system for insulin
Insulin in the form of inhalational powder is a newer form of insulin introduced 
in recent years. Human insulin inhalation powder was approved by the FDA in 2014. 
Inhaled human insulin is produced in Escherichia coli and is adsorbed onto fumaryl 
diketopiperazine and polysorbate 80 carrier particles. Inhalation powder is equiva-
lent unit for unit to insulin lispro. Its onset is 12–15 minutes, and it takes ~57 min-
utes to reach peak levels in plasma. The duration of action is ~2 hours. Inhaled 
human insulin is contraindicated in patients with chronic pulmonary obstructive 
disease as it may precipitate chronic bronchospasm. Sealed blister cards at room 
temperature must be discarded after 10 days. If kept in the refrigerator, they are 
good for use up to 1 month (Figure 2)[94, 95].
5.4 Glyburides-new hypoglycaemic drugs
A new advent in the field of glucose-lowering agents is glyburides. It is an oral 
hypoglycaemic class of drugs used for the management of type-II diabetes mellitus. 
Pharmacologically it belongs to sulphonylurea class of insulin secretagogues. These 
agents stimulate β cells of the pancreas to release insulin. The members of this class 
have different binding sites on their target pancreatic β-cell receptor. Their dose, 
rate of absorption, duration of action and route of elimination also differ from the 
conventional hypoglycaemic agents. Apart from lowering the blood glucose level 
directly, glyburide also increases peripheral glucose utilisation, decreases hepatic 
gluconeogenesis and may increase the number and sensitivity of insulin receptors. 
Glyburides proved to be advantageous over insulin because weight gain associated 
with it is less than in the case of insulin. However, one of its fallacies is that it may 
cause hypoglycaemia and require consistent food intake to decrease this risk. The risk 
of hypoglycaemia is increased in elderly, debilitated and malnourished individuals. 
Glyburide has been shown to decrease fasting plasma glucose, postprandial blood 
glucose and glycosylated haemoglobin (HbA1c) levels. It is metabolised in the liver. Its 
metabolites are excreted in urine and faeces in approximately equal proportions [96].
5.4.1 Indication
It is prescribed to be taken at meal time to lower the blood glucose level in 
patients with non-insulin-dependent diabetes mellitus where hyperglycaemia can-
not be controlled by diet alone.
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5.4.2 Half-life (t 1/2) and duration of action
The half-life of unchanged drug lies between 1 and 2 hours and its metabolites 
have an extended half-life of 10 hours. Duration of action is 12–24 hours.
5.4.3 Side effects
Nausea, heartburn, stomach fullness and weight gain may occur.
5.4.4 Precautions
• Contraindicated in hypersensitive patients.
• Given the high risk of hypoglycaemia associated with it. Patients must be counselled 
to avoid driving, the use of machinery or any activity that requires alertness or clear 
vision as low blood glucose levels may cause drowsiness, fatigue and blurred vision.
Figure 2. 
Insulin therapy for GD*.
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• Alcohol intake must be avoided under its medication as it aggravates hypogly-
caemia and may cause disulfiram-like reaction.
• Older adults may be more sensitive to the side effects of this drug, especially low 
blood sugar.
• During pregnancy, this medication should be used only when clearly needed. 
Pregnancy may cause or worsen diabetes.
Hypoglycaemia Considerations
Criteria • Mild hypoglycaemia: Blood glucose level is <4.0 mmol/L and may or may not be 
associated with symptoms of a low blood glucose level
• Severe hypoglycaemia: Blood glucose level is very low, generally <3.0 mmol/L, and 
is associated with confusion and potential loss of consciousness. The woman 
requires third-party assistance to manage the episode
Causes • Extensive physical activity
• Insulin overdose
• Lack or inadequate carbohydrate in meal
• Alcohol consumption (decreases blood glucose)
Symptoms • Hunger
• Light headedness/headache
• Sweating/shaking/weakness
• Tingling around the lips
• Irritability
• Blurred vision
• Severe hypoglycaemia (when unable to self-treat) can lead to confusion and loss 
of consciousness and requires urgent medical treatment
Treatment • Consume one 15-g serve of fast-acting carbohydrates (one of the following)
• 5–7 glucose candies
• Glass of soft drink rich in calories
• Three-heaped teaspoons of sugar or honey dissolved in water
• If after 15 minutes symptoms persist or BGL is less than 4.0 mmol/L, repeat one 
serve of fast-acting carbohydrates
• Do not overtreat with fast-acting carbohydrates as this may lead to rebound 
hyperglycaemia
• When BGL is 4.0 mmol/L or above, eat longer-lasting carbohydrate
• Eat a snack (e.g. sandwich or glass of milk) or usual meal if within 30 minutes
• Avoid overtreatment of hypoglycaemia resulting in hyperglycaemia
• Document BGL and time of hypoglycaemic episode
Lifestyle management • Plan to eat regular meals with adequate carbohydrate serves
• Be prepared and carry a food snack at all times (including while exercising)
• Aim to take long- or intermediate-acting insulin at the same time each day
• Identify causal factors of the hypoglycaemic episode and avoid/mitigate for the 
future
• Carry blood glucose metre at all times so BGL can be checked if symptoms 
present
Table 3. 
Aspects surrounding hypoglycaemia in women under oral hypoglycaemic drugs or insulin.
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• If glyburide is used, it may be switched to insulin at least 2 weeks before the 
expected delivery date because of glyburide’s risk of causing low blood sugar in 
your newborn.
• It is unknown if this medication passes into breast milk. However, similar 
drugs pass into breast milk [97].
5.5 Monitoring blood glucose levels in GD mothers
The blood glucose monitoring in gestational diabetic cases remains a bone of 
contention amongst clinicians worldwide. There have been various cohort studies 
propounding different procedures for blood glucose level monitoring. Some suggest 
the evaluation of HbA1C levels as accurate parameter; others suggest ultrasonogra-
phy and laboratory testing of postprandial blood glucose levels every 2 weeks. For 
women whose fasting blood glucose levels remain <105 md/dL are well managed 
alone with medical nutrition therapy, whereas for those whose blood glucose levels 
are >105 mg/dL require additional medical assistance including insulin therapy. 
The foetal abdominal circumference (AC) is also considered a pivotal parameter for 
monitoring the GD mothers. If the foetal AC is <70th percentile at 30 weeks, peri-
natal outcomes will be free from any complications with continued management on 
diet therapy and without glucose self-monitoring. The excess risk of macrosomia 
is attributed to women with a foetal AC >70th percentile at 30 weeks. Such preg-
nancies will benefit only from aggressive glucose lowering by insulin therapy. The 
fasting or preprandial glucose targets of 60–80 mg/dL have to be met in such cases 
to eliminate the excess risk of stillbirth [98–101].
5.6 Hypoglycaemia
Hypoglycaemia is uncommon in women with GD who are only on MNT; the risk 
of developing hypoglycaemia is however increased in women on pharmacotherapy, 
i.e. insulin or metformin. Hypoglycaemia incurs potent hazards to the health of 
the foetus. Hence, management of hypoglycaemia is also a crucial aspect in GD. If 
hypoglycaemia is asymptomatic, BGL results must be confirmed prior to starting 
the treatment (Table 3)[102].
6. Special obstetric care for pregnant women with GD
6.1 Antenatal care (ANC)
Antenatal care is defined as the procedure of regular check-ups that allow 
clinicians to treat and prevent potential health problems throughout the course of 
the pregnancy and to promote healthy lifestyles that benefit both the mother and 
child. In the case of pregnant women with GD, they must be closely monitored. GD 
women who are diagnosed before 20 weeks of pregnancy undergo foetal anatomical 
survey by means of ultrasonography within 18–20 weeks of pregnancy.
At 28–30 weeks of gestation, a foetal growth scan should be performed and 
repeated at 34–36 weeks of gestation. There should be at least 3-week gap between 
the two ultrasounds, and it should include foetal biometry and amniotic fluid 
estimation.
In GD women having uncontrolled blood glucose level or any other complication 
of pregnancy, the antenatal visits should be programmed at least once monthly as 
per the protocol for high-risk pregnancy.
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Monitoring of abnormal foetal growth and amniotic fluid volume for growth 
restriction and polyhydramnios, respectively, at each ANC visit is clinically impor-
tant. Pregnant women with GD should be diligently monitored for gestational 
hypertension, proteinuria and other obstetric complications.
Antenatal steroids in pregnant women with GD between 24 and 34 weeks of 
gestation requiring early delivery should be administered as per standardised guide-
lines. Most guidelines like FIGO suggest dexamethasone injection. More vigilant 
monitoring of blood glucose levels should be done for the next 72 hours following 
injection. In the case of raised blood glucose levels during this period, adjustment of 
insulin dose should be made as required [103–105].
6.2 Monitoring foetal health in pregnant women with GD
The rate of foetal morbidity in pregnant women with GD is more than the nor-
mal ones. This risk is further accelerated in pregnant women under drug manage-
ment. Hence vigilant foetal surveillance is required that includes foetal heart rate 
monitoring by auscultation on each antenatal care visit [105, 106].
6.3 Management of parturition in the case of GD
Pregnant women with GD but well controlled of blood glucose (2-hour 
PPBS <120 mg/dL) levels may be delivered at their respective health facil-
ity just like any normal pregnant woman. However, pregnant women with 
GD on insulin therapy with uncontrolled blood glucose levels (2-hour PPBS 
≥120 mg/dL) on MNT and physical exercise and metformin or insulin require-
ment >20 U/day should be referred at 34–36 weeks for delivery planning at 
Comprehensive Emergency Obstetric Care (CEmOC) centres under supervi-
sion of a gynaecologist [107].
6.4 Timing of delivery
Most GD pregnancies are associated with delayed lung maturity of the foetus; 
hence routine delivery prior to 39 weeks is not recommended. Such referred cases 
must get assured indoor admission or can be kept in a birth waiting home with 
round-the-clock availability of gynaecologist for monitoring.
Managing the delivery timing in GD mother is very crucial if pregnant 
women with GD and well-controlled blood glucose have not undergone parturi-
tion spontaneously; induction of labour should be scheduled at or after 39 weeks 
of pregnancy.
If pregnant women with GD present poor blood glucose levels, accompanied 
with risk factors like gestational hypertension, previous stillbirth and other com-
plications, then the timing of delivery has to be individualised by the obstetrician 
accordingly.
Vaginal delivery is preferred, and lower segment caesarean section (LSCS) is 
done for obstetric indications only such as in the case of foetal macrosomia, a condi-
tion where the estimated foetal weight is >4 kg where vaginal delivery may cause 
shoulder dystocia in the newborn.
Regular blood glucose monitoring of the pregnant women with GD on metfor-
min or insulin is required during labour. The morning dose of insulin/metformin is 
withheld on the day of induction of labour, and pregnant women are subjected to 2 
hourly monitoring of blood glucose.
IV infusion with normal saline (NS) is to be started and regular insulin to be 
added according to blood glucose levels as per Table 4 [105–108].
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6.4.1 Neonatal care for baby of a GD mother
Immediate and timely management of all neonates in a proper NICU facility 
emphasising on early breastfeeding is done on a priority basis to prevent hypogly-
caemia. Under any emergency situations, the sick neonates must be immediately 
resuscitated as per standard guidelines.
Hypoglycaemia monitoring of the newborn is started within an hour of delivery and 
repeated every 4 hours (prior to next feed) until four stable glucose values are obtained.
The newborn with the normal birth weight and blood glucose level of <45 mg/dL 
is considered hypoglycaemic and requires immediate medical management. In the 
case of intrauterine growth restriction (IUGR), newborns’ Blood Glucose level limit 
is <54 mg/dL [108].
6.4.2 Diagnosis of hypoglycaemia
The glucometers’ testing method is not very reliable for diagnosis of hypogly-
caemia as their precision decreases at lower blood glucose level. The most definite 
diagnosis of hypoglycaemia is by measurement of blood glucose using established 
laboratory methods such as glucose oxidase method by calorimeter. However, if 
laboratory facility is unavailable at the place of childbirth, then the treating physi-
cian can take a decision to send a blood glucose sample to the laboratory at the near-
est location without delaying the next management step. However, under adverse 
circumstances, blood glucose values obtained by glucometers may be considered for 
all operational steps if it’s the question of newborn’s wellbeing.
6.4.3 Symptoms of hypoglycaemia
Symptoms of hypoglycaemia are difficult to observe as in most cases it is 
asymptomatic, variable and observed only in a smaller proportion of patients or 
newborns:
• Stupor or apathy
• Jitteriness or tremors
• Episodes of cyanosis
• Convulsions
• Intermittent apnoeic spells or tachypnoea
• Weak and high-pitched cry, limpness and lethargy
Blood glucose level Amount of insulin to be added in  
500 mL of NS
Rate of NS infusion
90–120 mg/dL 0 100 ml/hour (16 drops/min)
120–140 mg/dL 4 U 100 ml/hour (16 drops/min)
140–180 mg/dL 6 U 100 ml/hour (16 drops/min)
>180 mg/dL 8 U 100 ml/hour (16 drops/min)
Table 4. 
Rate and amount of insulin-normal saline infusion in relation to blood glucose level.
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• Difficulty in feeding
• Eye rolling
• Episodes of sweating
• Any unexplained clinical feature in baby of diabetic mother
6.4.4 Management of hypoglycaemia in newborn
All cases of newborn with hypoglycaemia should be managed in the following 
manner:
6.4.4.1 Step 1
Whether there are any symptoms of hypoglycaemia or not, if a baby is born to 
a GD mother, its blood glucose level must be checked immediately between 1 and 
2 hours after birth. If blood glucose values are <45 mg/dL, this should be considered 
as ‘hypoglycaemia’. The primary management in such cases is that the newborn 
should be given breastfeed without any delay. Direct breastfeeding is the best man-
agement step for neonatal hypoglycaemia. If the infant is unable to suck, expressed 
breast milk from the mother should be given. If the mother is not in a position to 
give breastfeed or in the case of no breast milk secretion, the baby should be given 
any formula feed. If the lactation management centres (human milk banks) are 
available at the facility, then it can also be involved in feeding the baby.
After an hour of breastfeeding the newborn, blood glucose level must be moni-
tored again. If it is found to be more than 45 mg/dL, 2 hourly feeding (breastfeeding 
if not available, formula feed can be given) should be ensured by explaining to the 
mother/relatives and supervised.
6.4.4.2 Step 2
If at any point of time the blood glucose level drops below 20 mg/dL, immediate 
intravenous bolus injection of 10% dextrose at 2 mL/kg body weight of baby should 
be given. This should be followed by intravenous infusion of 10% of dextrose at a 
rate of 100 mL/kg/day. Blood glucose should be checked 30 minutes after starting 
the infusion. If it is still less than 20 mg/dL, the infant should be referred to a higher 
centre where a paediatrician is available [109, 110].
6.4.5 Postdelivery follow-up of pregnant women with GD
Immediate postpartum care required for women with GD is a lot similar to that 
for women without GD, but these women are at high risk to develop type 2 diabetes 
mellitus in the future, although in 80% of cases, the glucose level usually returns to 
normal postdelivery.
Subsequently, ANC must be performed 75-g OGTT (fasting and 2-hour PP) at 
6 weeks postpartum to evaluate glycaemic status of a woman. Cut-off for normal 
plasma and abnormal blood glucose levels in the fasting and 75-g OGTT values are 
[111–113]:
• Fasting blood glucose (≥126 mg/dL)
• 75-g OGTT (2-hour blood glucose)
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• Normal (<140 mg/dL)
• IGT (140–199 mg/dL)
• Diabetes (≥200 mg/dL)
7. Conclusion
This chapter summarises all the clinical aspects surrounding gestational diabe-
tes, ranging from its pathophysiology, aetiology right to its proper clinical manage-
ment, for both the mother and the newborn, to a GD mother. Pregnancy affects 
both the maternal and foetal metabolisms, and even the nondiabetic woman exerts 
a diabetogenic effect. Amongst pregnant women, 2–17.8% develop GD. Metabolic 
changes in the normal pregnant women also have a degree of insulin resistance that 
shunts glucose preferentially to the foetus. To maintain blood glucose levels within 
a tight range, the normal pregnant woman must increase her insulin secretion up 
to fourfold. When the pancreas is not able to compensate for the increased insulin 
needs of pregnancy, GD occurs resulting in hyperglycaemia and hyperinsulinemia.
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